Immunomodulators

Immunomodulators

1. Definition, terminology & conceptual framework

• Immunomodulator — an umbrella term for any agent that alters (up- or down-regulates) the magnitude, quality or specificity of an immune response; in G&G's framing, immunomodulators are therapeutic approaches "targeted to a specific molecular driver of the immune response (e.g., cytokines)," as distinct from broad immunosuppression which is "the overall reduction in the magnitude of the immune response" (G&G 14e Ch.39, p.780).
• Immunostimulant / immunopotentiator — an agent that enhances host immune responsiveness; the primary focus of this topic. Used in cancer immunotherapy, chronic/refractory infection and immunodeficiency states (G&G 14e Ch.39, pp.780–784).
• Biological response modifier (BRM) — a recombinant protein, cytokine, or monoclonal/polyclonal antibody that "modifies the biological responses to tumour cells"; KDT lists interferon-α2, interleukin-2 and TNF among cytokines "used as adjuvants in treating neoplasms… [with] some direct inhibitory effect on malignant cells, in addition to reinforcing immunological defence" (KDT 8e Ch.64, p.~931).
• Immunoadjuvant — a substance co-administered with antigen to amplify the magnitude, quality and duration of the adaptive response by first engaging the innate immune system (G&G 14e Ch.40, p.812).
• Key conceptual axis — immunomodulation can be non-specific (broad innate activation, e.g. BCG, glucan, levamisole) or specific/targeted (a defined molecular target — a cytokine, a costimulatory pair, an immune checkpoint, a surface CD antigen). The modern era is dominated by the specific class because precise targeting limits the off-target toxicity that plagues global immunosuppression (G&G 14e Ch.39, pp.769–770, 780).
• ⚠ Naming caution — many "biologicals" can act as either immunostimulant or immunosuppressant depending on the target: blocking an inhibitory checkpoint (PD-1, CTLA-4) stimulates immunity (cancer therapy), whereas blocking a stimulatory cytokine (TNFα, IL-6) suppresses immunity (autoimmune disease). The molecule's directionality, not its chemistry, defines its class (G&G 14e Ch.39, Fig.39–5, p.780).